FJ
Therapeutic Areas
Keros Therapeutics Pipeline
| Drug | Indication | Phase |
|---|---|---|
| KER-050 (Eltrapuldencel) | Anemia in patients with myelodysplastic syndromes (MDS) | Phase 2 |
| KER-050 | Anemia in patients with myelofibrosis | Phase 2 |
| KER-012 | Pulmonary Arterial Hypertension (PAH) | Phase 2 |
| KER-065 | Obesity and related disorders | Phase 1 |
| KER-047 | Iron metabolism disorders | Phase 1 |
Leadership Team at Keros Therapeutics
JS
Jasbir S. Seehra, Ph.D.
President, Chief Executive Officer, and Director
KR
Keith Regnante, CPA
Chief Financial Officer
SJ
Simon J. Cooper, M.B. B.Chir., M.Sc.
Chief Medical Officer
CR
Christopher R. Bowman, M.D.
Senior Vice President, Clinical Development
KB
Katherine Breedis
Vice President, General Counsel
JE
James E. Audia, Ph.D.
Chairman of the Board
JC
Julian C. Baker
Director
CP
Christopher Peetz
Director
PJ
Pablo J. Cagnoni, M.D.
Director
JL
Jennifer L. Good
Director